10-Q: BioCardia Q1 2026 Results: Cash Burn Continues, Regulatory Progress

BioCardia, Inc. reported its first quarter 2026 financial results, highlighting ongoing development of its cell therapies and progress with regulatory bodies, while facing significant cash burn and Nasdaq listing concerns.

Summary

• BioCardia, Inc. reported a net loss of $2.26 million for the first quarter ended March 31, 2026, compared to a net loss of $2.71 million for the same period in 2025.
• Total costs and expenses decreased to $2.27 million from $2.73 million year-over-year, driven by lower research and development and selling, general, and administrative expenses.
• The company's cash and cash equivalents significantly decreased to $0.95 million as of March 31, 2026, from $2.50 million as of December 31, 2025.
• Management estimates that current cash is insufficient to fund planned expenditures beyond June 2026, raising substantial doubt about the company's ability to continue as a going concern.
• BioCardia is actively pursuing additional capital through various means, including debt, equity, and collaboration agreements.
• The company received a notice from Nasdaq on April 10, 2026, for non-compliance with the minimum stockholders' equity requirement of $2.5 million.
• Significant progress was made in regulatory discussions with the FDA for the CardiAMP Cell Therapy System and the Helix delivery system, and with Japan's PMDA for CardiAMP.
• The CardiAMP HF II Phase III trial is underway, and the CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial is progressing, with initial results presented.
• The allogeneic MSC therapy trial for HFrEF has completed its low-dose cohort with no adverse events reported.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant cash burn, going concern warning, and Nasdaq listing issues, despite positive regulatory developments.

Positives

• Positive regulatory feedback received from the FDA for both the CardiAMP Cell Therapy System and the Helix delivery system, with the FDA recommending Premarket Approval (PMA) submission and continued support for the CardiAMP HF II trial.
• Japan's PMDA indicated that clinical safety and efficacy evidence for the CardiAMP Cell Therapy in ischemic heart failure is likely sufficient for market clearance, with a preliminary Advisory Record received in May 2026.
• The low-dose cohort of the allogeneic MSC therapy trial for HFrEF showed no treatment-emergent adverse events, arrhythmias, rejection, or allergic responses, and the Data Safety Monitoring Board recommended proceeding.
• Results from the CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial's open-label roll-in cohort showed significant improvements in exercise tolerance and reduction in angina episodes.
• Research and development expenses decreased by approximately 19.3% year-over-year, indicating cost management efforts.
• Selling, general, and administrative expenses decreased by approximately 13.8% year-over-year, also indicating cost management.

Negatives

• The company has a substantial accumulated deficit of approximately $170.6 million as of March 31, 2026.
• Cash and cash equivalents decreased by approximately 61.9% to $0.95 million from $2.50 million in the quarter.
• Management estimates that current cash is insufficient to fund planned expenditures and meet obligations beyond June 2026, raising substantial doubt about the ability to continue as a going concern.
• The company received a Nasdaq non-compliance notice regarding insufficient stockholders' equity ($895,000 as of December 31, 2025, below the $2.5 million minimum).
• The CardiAMP HF pivotal trial did not meet its primary endpoint, although secondary analyses showed promising trends in specific patient subgroups.
• The company may be forced to reduce operating expenses, delay or reduce the scope of product development programs, or cease operations if adequate funds are not raised.

Risks

• Failure to regain compliance with Nasdaq listing requirements could lead to delisting, potentially decreasing trading volume, share price, and making capital raising more difficult.
• Substantial doubt exists about the company's ability to continue as a going concern beyond one year from the financial statement issuance date due to insufficient cash reserves.
• The company's ability to continue development beyond June 2026 is contingent on raising additional capital, which is not guaranteed and may be on highly dilutive terms.
• Clinical trials may not be successful, or regulatory approvals may not be obtained, which would significantly impact the company's ability to generate revenue.
• The company's product candidates are in clinical development, and there is no assurance of their safety or efficacy.
• Competition from other companies developing similar therapies could impact market share and profitability.
• The company's reliance on third-party manufacturers and suppliers could lead to disruptions in production.
• Intellectual property protection is crucial, and any challenges to patents or proprietary technology could adversely affect the business.

Future Outlook

The company anticipates continued operating losses and negative cash flows for the next several years. Future development and operations beyond June 2026 are contingent on raising additional capital through various means, including debt, equity, and collaboration agreements. The company plans to increase research and development expenses as it advances its pivotal trials and begins new ones.

Management Comments

• Management believes our cash and cash equivalents of $951,000 as of March 31, 2026 are not sufficient to fund our planned expenditures and meet our obligations beyond June 2026.
• These factors raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued.
• Our ability to continue as a going concern and to continue further development of our therapeutic candidates beyond June 2026 will require us to raise additional capital.
• While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within their control and cannot be assessed as being probable of occurring.
• If adequate funds are not available, we may be required to reduce operating expenses, delay or reduce the scope of our product development programs, obtain funds through arrangements with others that may require us to relinquish rights to certain of our technologies or products that we would otherwise seek to develop or commercialize, or cease operations.

Industry Context

StockSavvy.ai notes that BioCardia's Q1 2026 filing reflects the challenging financial landscape for clinical-stage biotechnology companies, particularly those with significant cash burn and ongoing clinical trials. The company's progress in regulatory discussions with the FDA and PMDA is a positive sign, but the immediate need for capital and the Nasdaq listing concerns highlight the inherent risks in this sector. The focus on cardiovascular diseases with unmet needs positions BioCardia in a critical therapeutic area, but execution and funding remain paramount.

Comparison to Industry Standards

• Companies in the clinical-stage biotechnology sector often experience significant net losses and negative cash flows from operations, similar to BioCardia's situation.
• The need for substantial capital raises is a common characteristic of the industry, with many companies relying on equity financings, debt, and strategic partnerships to fund development.
• Regulatory pathways for novel cell therapies, such as BioCardia's CardiAMP, are complex and lengthy, with companies like Kite Pharma (now Gilead) and Novartis experiencing extensive review periods for CAR-T therapies.
• The Nasdaq listing requirements, particularly for minimum stockholders' equity, are standard for companies listed on major exchanges. Failure to meet these can lead to delisting, a risk faced by many smaller biotech firms.
• The development timelines for cardiovascular therapies can be lengthy, with pivotal Phase III trials often requiring significant patient enrollment and long-term follow-up, as seen in BioCardia's ongoing trials.

Legal Proceedings

• Management is not aware of any current legal or administrative proceedings that are likely to have an adverse effect on the business, financial position, results of operations, or cash flows.

Stakeholder Impact

• Shareholders may experience further dilution if additional equity is raised on unfavorable terms.
• The potential delisting from Nasdaq could negatively impact share liquidity and investor confidence.
• Employees may face uncertainty regarding job security if the company is forced to reduce operations due to funding shortfalls.
• Partners and collaborators may be concerned about the company's financial stability and its ability to fulfill future commitments.

Next Steps

• Submit a plan to Nasdaq by May 25, 2026, to regain compliance with listing requirements.
• Continue advancing the CardiAMP HF II Phase III trial.
• Advance the CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial, with primary results from the roll-in cohort presented at Euro PCR in May 2026.
• Continue development of the allogeneic MSC therapy for HFrEF, with Phase 2 development anticipated in the US and Japan.
• Prepare answers to outstanding questions from PMDA and advance towards Shonin submission for CardiAMP in Japan.
• Continue discussions with the FDA regarding the PMA submission for the CardiAMP Cell Therapy System and the Helix delivery system.
• Seek additional capital through various financing and partnership arrangements to fund operations beyond June 2026.

Key Dates

Recommendation

The company shows promising regulatory progress and scientific development in a critical area of unmet medical need. However, the severe cash burn, going concern warning, and Nasdaq listing issues present significant immediate risks. Investors should hold positions while monitoring capital raise efforts and regulatory milestones, as the potential upside is high but the downside risk is substantial.

Keywords

BioCardia, Form 10-Q, Quarterly Report, Cell Therapy, Cardiovascular Disease, Heart Failure, Chronic Myocardial Ischemia, FDA, PMDA, Clinical Trials, Biotechnology, Biopharmaceutical, Nasdaq, Going Concern, Capital Raise